Johnson & Johnson Innovation to provide new funding and support for European research companies

US health care giant Johnson & Johnson (NYSE: JNJ), through its J&J Innovation unit, has launched JLINX, an initiative to support early-stage European companies to pursue research.

JLINX, a collaboration with Janssen Pharmaceutica NV, will offer scientists and entrepreneurs access to venture funding, research and development (R&D) expertise and state-of-the-art facilities.

Located in a fully dedicated facility on the Janssen campus in Beerse, Belgium, it is designed to catalyze scientific innovations by offering start-ups flexible ways to grow and collaborate across the European life science ecosystem.